iodoform
Small moleculeexperimental
Iodoform is an organic compound with the formula CHI3. It was formerly used as an antiseptic wound powder. Iodoform is commonly used as radiopacifier for primary tooth root canal fllling, but its use in endodontics is controversial because of its potential for causing toxic effects. It is also used in veterinary medicine as an active ingredient in the ear powders for dogs and cats. — NCATS
Clinical trial activity
11 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
3
Phase 4
4
Earliest trial started Jan 1, 2013 (NCT01491659)
Timeline
Indications
Approved for
Studied for
- Alveolitis, Extrinsic Allergic · Phase 4
- Colitis, Ulcerative · Phase 1
- Dental Pulp · Phase 2/Phase 3
- Dental Pulp Cavity · Phase 3
- Diarrhea · Phase 4
- Dry Socket · Phase 4
- Inflammation · Phase 4
- Inflammatory Bowel Diseases · Phase 1
- Postoperative Pain · Phase 2/Phase 3
- Procedural Pain · Phase 4
- Tooth · Phase 3
- Tooth Abnormalities · Phase 4
- Wound Healing · Phase 1
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Loading structure…
SMILES
IC(I)I- Mol. weight
- 393.7321 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIodoform ↗
- NCATSKXI2J76489 ↗
- ChEMBLCHEMBL1451116 ↗
Also known as
- carbon triiodide
- carbon triiodide
- carbon triiodide
- guedes pinto
- idoform
- iodoform
- iodoform
- iodoform
- iodoform
- iodoform
- iodoform
- iodoform
- iodoform
- iodoform
- methyl triiodide
- methyl triiodide
- triiodomethane
- triiodomethane
- triiodomethane
- triiodomethane
- tri-iodomethane
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06755502 | N/A | Aug 8, 2025 | Cairo University |
| NCT06456060 | Phase 1 | Jun 1, 2024 | Watim Medical |
| NCT06144983 | Phase 4 | Feb 1, 2022 | University of Baghdad |
| NCT05334745 | Phase 1 | Dec 1, 2021 | Cairo University |
| NCT04241029 | Phase 1 | Jan 20, 2020 | South-Eastern Norway Regional Health Authority, University of Oslo |
| NCT03741894 | Phase 4 | Sep 1, 2018 | University of Pecs |
| NCT03402321 | Phase 4 | Apr 1, 2018 | Cairo University |
| NCT04547764 | Phase 3 | Jun 1, 2017 | King Abdul-Aziz University |
| NCT03084601 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2016 | Cairo University |
| NCT02216942 | Phase 3 | Jan 1, 2015 | Fausto Medeiros Mendes, University of Sao Paulo |
| NCT01491659 | Phase 4 | Jan 1, 2013 | Danisco, Pfizer |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cairo University | Academic/Hospital | 4 | 4 | 4 | 2016 |
| Danisco | For profit | 1 | 0 | 1 | 2013 |
| Fausto Medeiros Mendes | Academic/Hospital | 1 | 1 | 1 | 2015 |
| King Abdul-Aziz University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Pfizer | For profit | 1 | 1 | 1 | 2013 |
| South-Eastern Norway Regional Health Authority | Government | 1 | 0 | 1 | 2020 |
| University of Baghdad | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Oslo | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Pecs | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Sao Paulo | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Watim Medical | Academic/Hospital | 1 | 1 | 1 | 2024 |
11 organizations
Page 1 / 1